The Role of CTGF in Osteosarcoma Progression

Ilkyu Han; Mi Ra Lee; Han-Soo Kim

doi:10.5292/jkbjts.2014.20.1.1

Journal List > J Korean Bone Joint Tumor Soc > v.20(1) > 1052039

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Han, Lee, and Kim: The Role of CTGF in Osteosarcoma Progression

Original Article

J Korean Bone Joint Tumor Soc 2014;20(1):1-6.

Published online: 10 June 2014

DOI: https://doi.org/10.5292/jkbjts.2014.20.1.1

The Role of CTGF in Osteosarcoma Progression

Ilkyu Han, Mi Ra Lee, Han-Soo Kim

Department of Orthopaedic Surgery, Seoul National University Hospital, Seoul, Korea

Correspondence to: Han-Soo Kim Department of Orthopaedic Surgery, Seoul National University Hospital, 101 Daehak-no, Jongno-gu, Seoul 110-744, Korea TEL: +82-2-2072-2362 FAX: +82-2-764-2718 E-mail: hankim@snu.ac.kr

Received 31 March 2014 Revised 29 May 2014 Accepted 4 June 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To examine the expression of Connective Tissue Growth Factor (CTGF) in osteosarcoma and to evaluate its role in osteosarcoma invasion and proliferation.

Materials and Methods

The mRNA expression of CTGF from 23 patient-derived osteosarcoma cell lines was examined, and the role of CTGF in cell invasion and proliferation was examined using siRNA transfection.

Results

The over-expression of CTGF mRNA was observed in 17 cell lines (74%). CTGF-specific siRNA transfection into SaOS-2 and MG63 cell lines resulted in efficient knockdown of CTGF expression on Western blot analysis. siRNA transfected cells showed decreased migration on Matrigel invasion assay and decreased cell proliferation on WST-1 assay.

Conclusion

These results indicated that the CTGF expression may play an important role in osteosarcoma progression, and may be a therapeutic target of osteosarcoma.

Keywords: osteosarcoma, connective tissue growth factor, CCN, CTGF, cancer progression

References

1. Geller DS, Gorlick R. HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies. Expert Opin Pharmacother. 2010; 11:51–61.

2. Janeway KA, Barkauskas DA, Krailo MD, et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer. 2012; 118:4597–605.

3. Holbourn KP, Acharya KR, Perbal B. The CCN family of proteins: structure-function relationships. Trends Biochem Sci. 2008; 33:461–73.

4. Pan LH, Beppu T, Kurose A, et al. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma. Neurol Res. 2002; 24:677–83.

5. Dhar A, Ray A. The CCN family proteins in carcinogenesis. Exp Oncol. 2010; 32:2–9.

6. Lin MT, Kuo IH, Chang CC, et al. Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 upregulation in Cyr61/CCN1-induced gastric cancer cell invasion. J Biol Chem. 2008; 283:15807–15.

7. Manara MC, Perbal B, Benini S, et al. The expression of ccn3 (nov) gene in musculoskeletal tumors. Am J Pathol. 2002; 160:849–59.

8. Moritani NH, Kubota S, Sugahara T, Takigawa M. Comparable response of ccn1 with ccn2 genes upon arthritis: An in vitro evaluation with a human chondrocytic cell line stimulated by a set of cytokines. Cell Commun Signal. 2005; 3:6.

9. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 2001; 61:8917–23.

10. Chen PP, Li WJ, Wang Y, et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One. 2007; 2:e534.

11. Deng YZ, Chen PP, Wang Y, et al. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem. 2007; 282:36571–81.

12. Clark JC, Akiyama T, Thomas DM, et al. RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer. 2011; 117:3517–28.

13. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol. 2009; 41:771–83.

14. Kubota S, Takigawa M. CCN family proteins and angiogenesis: from embryo to adulthood. Angiogenesis. 2007; 10:1–11.

Figure 1.

mRNA Expression of CTGF in 23 patient-derived osteosarcoma cell lines. Human osteoblast cell line (hFOb 1.19) was used as the control cell line.

Figure 2.

siRNA knockdown of CTGF in osteosarcoma cell lines. (A, B) Western blot analysis and (C, D) Real-time PCR. MG63 (A, C) and SaOS-2 (B, D) cell lines were used. *p<0.05.

Figure 3.

Representative microscopic image (×100) of Matrigel invasion assay. The number in the CTGF-siRNA transfected cells (B) is reduced compared to the control cells (A).

Figure 4.

Effect of CTGF in osteosarcoma proliferation. The number of viable cells is reduced in the CTGF-siRNA transfected cells. MG63 (A) and SaOS-2 (B) cell lines were used. *p<0.05.

TOOLS

Similar articles